{"id":745043,"date":"2014-01-15T18:59:00","date_gmt":"2014-01-15T18:59:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/"},"modified":"2023-03-22T00:04:59","modified_gmt":"2023-03-22T04:04:59","slug":"merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/","title":{"rendered":"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine"},"content":{"rendered":"<p>\n      Merck (NYSE:<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.dailyfinance.com%2Fquotes%2FMRK%2Fusa&#038;esheet=50784422&#038;newsitemid=20140115006454&#038;lan=en-US&#038;anchor=MRK&#038;index=1&#038;md5=7cf7605cdb4ba3e9450622cbbee3611a\" rel=\"nofollow\">MRK<\/a>),<br \/>\n      known as MSD outside the United States and Canada, today said it was<br \/>\n      pleased with the U.S. Food and Drug Administration (FDA)\u2019s<br \/>\n      Cardiovascular and Renal Drugs Advisory Committee\u2019s recommendation for<br \/>\n      approval of vorapaxar. Vorapaxar is the company\u2019s investigational<br \/>\n      antiplatelet medicine for the reduction of atherothrombotic events, when<br \/>\n      added to standard of care, in patients with a history of heart attack<br \/>\n      and no history of stroke or transient ischemic attack.\n    <\/p>\n<p>\n      \u201cThere are approximately 7.6 million Americans who have survived a heart<br \/>\n      attack. Each year, about 190,000 of them have a recurrent heart attack,<br \/>\n      so there remains a need for additional treatment options,\u201d said Dr.<br \/>\n      Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck<br \/>\n      Research Laboratories. \u201cThe results of today\u2019s Advisory Committee mark<br \/>\n      an important milestone in our effort to bring vorapaxar to appropriate<br \/>\n      patients with a history of heart attack. We look forward to working with<br \/>\n      the FDA as it completes its review.\u201d\n    <\/p>\n<p>\n      The FDA is not bound by the Committee\u2019s guidance, but takes its advice<br \/>\n      into consideration when reviewing investigational medicines.\n    <\/p>\n<p>\n      <b>About Vorapaxar<\/b>\n    <\/p>\n<p>\n      Vorapaxar, proposed trade name ZONTIVITY\u2122, is a first-in-class<br \/>\n      protease-activated receptor-1 (PAR-1) antagonist designed to inhibit the<br \/>\n      formation of blood clots. PAR-1 is a receptor activated by thrombin,<br \/>\n      known to be a potent platelet activator. Vorapaxar inhibits<br \/>\n      thrombin-induced platelet aggregation by inhibiting PAR-1 receptors on<br \/>\n      platelets.\n    <\/p>\n<p>\n      Data supporting the filing of this new drug application are from the<br \/>\n      26,449 patient TRA 2\u00b0P &#8211; TIMI 50 trial, a randomized, double-blind,<br \/>\n      placebo-controlled study of vorapaxar used in addition to standard<br \/>\n      therapy including other antiplatelet agents. Patients included in the<br \/>\n      study had a history of myocardial infarction, ischemic stroke, or<br \/>\n      peripheral artery disease and had a median follow-up of 2.5 years.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global healthcare leader working to help the world be<br \/>\n      well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies, and<br \/>\n      consumer care and animal health products, we work with customers and<br \/>\n      operate in more than 140 countries to deliver innovative health<br \/>\n      solutions. We also demonstrate our commitment to increasing access to<br \/>\n      healthcare through far-reaching policies, programs and partnerships. For<br \/>\n      more information, visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&#038;esheet=50784422&#038;newsitemid=20140115006454&#038;lan=en-US&#038;anchor=vip2-msd.com\/merckcom-migrated&#038;index=2&#038;md5=6789d6fc3ded411d9e148dfc73ffb65a\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=https%3A%2F%2Ftwitter.com%2FMerck&#038;esheet=50784422&#038;newsitemid=20140115006454&#038;lan=en-US&#038;anchor=Twitter&#038;index=3&#038;md5=7334baf5504f6d674f6c552da738e6f2\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&#038;esheet=50784422&#038;newsitemid=20140115006454&#038;lan=en-US&#038;anchor=Facebook&#038;index=4&#038;md5=c02f41a6703b50e0804b4a7b313852ab\" rel=\"nofollow\">Facebook<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.youtube.com%2FMerck&#038;esheet=50784422&#038;newsitemid=20140115006454&#038;lan=en-US&#038;anchor=YouTube&#038;index=5&#038;md5=e1dd1598c8ae966345cddce7c0632703\" rel=\"nofollow\">YouTube<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement<\/b>\n    <\/p>\n<p>\n      This news release includes \u201cforward-looking statements\u201d within the<br \/>\n      meaning of the safe harbor provisions of the United States Private<br \/>\n      Securities Litigation Reform Act of 1995. These statements are based<br \/>\n      upon the current beliefs and expectations of Merck\u2019s management and are<br \/>\n      subject to significant risks and uncertainties. There can be no<br \/>\n      guarantees with respect to pipeline products that the products will<br \/>\n      receive the necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; Merck\u2019s ability to accurately<br \/>\n      predict future market conditions; manufacturing difficulties or delays;<br \/>\n      financial instability of international economies and sovereign risk;<br \/>\n      dependence on the effectiveness of Merck\u2019s patents and other protections<br \/>\n      for innovative products; and the exposure to litigation, including<br \/>\n      patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      Merck undertakes no obligation to publicly update any forward-looking<br \/>\n      statement, whether as a result of new information, future events or<br \/>\n      otherwise. Additional factors that could cause results to differ<br \/>\n      materially from those described in the forward-looking statements can be<br \/>\n      found in Merck\u2019s 2012 Annual Report on Form 10-K and the company\u2019s other<br \/>\n      filings with the Securities and Exchange Commission (SEC) available at<br \/>\n      the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&#038;url=http%3A%2F%2Fwww.sec.gov&#038;esheet=50784422&#038;newsitemid=20140115006454&#038;lan=en-US&#038;anchor=www.sec.gov&#038;index=6&#038;md5=f1893002c7408987b4c5ef28c79a1e45\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      ZONTIVITY\u2122 is a registered trademark of Merck &#038; Co., Inc., Whitehouse<br \/>\n      Station, N.J., USA\n    <\/p>\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&#038;sty=20140115006454r1&#038;sid=hq1sf1&#038;distro=nx\" \/><span class=\"bwct31415\"\/><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>or<br \/>Patrick        Witmer, 267-305-4910<br \/>or<br \/>Investors:<br \/>Carol Ferguson,        908-423-4465<br \/>or<br \/>Justin Holko, 908-423-5088     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)\u2019s Cardiovascular and Renal Drugs Advisory Committee\u2019s recommendation for approval of vorapaxar. Vorapaxar is the company\u2019s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack. \u201cThere are approximately 7.6 million Americans who have survived a heart attack. Each year, about 190,000 of them have a recurrent heart attack, so there remains a need for additional treatment options,\u201d said Dr. Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck Research Laboratories. \u201cThe results of today\u2019s Advisory Committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack. We look forward to working with the FDA as it<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289,56],"class_list":["post-745043","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)\u2019s Cardiovascular and Renal Drugs Advisory Committee\u2019s recommendation for approval of vorapaxar. Vorapaxar is the company\u2019s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack. \u201cThere are approximately 7.6 million Americans who have survived a heart attack. Each year, about 190,000 of them have a recurrent heart attack, so there remains a need for additional treatment options,\u201d said Dr. Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck Research Laboratories. \u201cThe results of today\u2019s Advisory Committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack. We look forward to working with the FDA as it\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2023-03-22T04:04:59+00:00\" \/>\n<meta property=\"og:image\" content=\"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/\",\"name\":\"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/#primaryimage\"},\"thumbnailUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx\",\"datePublished\":\"2014-01-15T18:59:00+00:00\",\"dateModified\":\"2023-03-22T04:04:59+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/#primaryimage\",\"url\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx\",\"contentUrl\":\"http:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/","og_locale":"en_US","og_type":"article","og_title":"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine - Merck.com","og_description":"Merck (NYSE: MRK ), known as MSD outside the United States and Canada, today said it was pleased with the U.S. Food and Drug Administration (FDA)\u2019s Cardiovascular and Renal Drugs Advisory Committee\u2019s recommendation for approval of vorapaxar. Vorapaxar is the company\u2019s investigational antiplatelet medicine for the reduction of atherothrombotic events, when added to standard of care, in patients with a history of heart attack and no history of stroke or transient ischemic attack. \u201cThere are approximately 7.6 million Americans who have survived a heart attack. Each year, about 190,000 of them have a recurrent heart attack, so there remains a need for additional treatment options,\u201d said Dr. Daniel Bloomfield, vice president, Cardiovascular Diseases, Merck Research Laboratories. \u201cThe results of today\u2019s Advisory Committee mark an important milestone in our effort to bring vorapaxar to appropriate patients with a history of heart attack. We look forward to working with the FDA as it","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/","og_site_name":"Merck.com","article_modified_time":"2023-03-22T04:04:59+00:00","og_image":[{"url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/","name":"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"primaryImageOfPage":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/#primaryimage"},"image":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/#primaryimage"},"thumbnailUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx","datePublished":"2014-01-15T18:59:00+00:00","dateModified":"2023-03-22T04:04:59+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/#primaryimage","url":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx","contentUrl":"http:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20140115006454r1&sid=hq1sf1&distro=nx"},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-statement-on-fda-advisory-committee-for-vorapaxar-mercks-investigational-antiplatelet-medicine\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Statement on FDA Advisory Committee for Vorapaxar, Merck\u2019s Investigational Antiplatelet Medicine"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"9aac2555-0142-41d4-951a-db6e28041a95","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745043","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":0,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745043\/revisions"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745043"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745043"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}